CALC
HEALTHCARECalciMedica Inc
Live · NASDAQ · May 9, Close
What's Moving CALC Today?
No stock-specific AI insight has been generated for CALC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.62
Fundamentals
Trading
CALC News
15 articles- [SCHEDULE 13G/A] CalciMedica, Inc. Amended Passive Investment DisclosureStock Titan·May 8, 2026
- CalciMedica Reports 2025 Financial Results and Provides Clinical UpdatesYahoo Finance·Mar 3, 2026
- CalciMedica’s stock drops 75% on acute kidney injury trial terminationClinicaltrialsarena·Jan 29, 2026
- CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee RecommendationYahoo Finance·Jan 28, 2026
- CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesYahoo Finance·Nov 12, 2025
- CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial HypertensionYahoo Finance·Nov 12, 2025
- CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025Yahoo Finance·Nov 10, 2025
- CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™Yahoo Finance·Oct 14, 2025
- CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesYahoo Finance·Aug 12, 2025
- CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual ConferenceYahoo Finance·Jul 8, 2025
- CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory FailureYahoo Finance·Jun 25, 2025
- CalciMedica Insiders Added US$1.05m Of Stock To Their HoldingsYahoo Finance·Jun 13, 2025
- CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology MeetingYahoo Finance·Jun 12, 2025
- CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesYahoo Finance·May 14, 2025
All 15 articles loaded
Price Data
52-Week Range
$0.62
Fundamentals
Trading
About CalciMedica Inc
CalciMedica, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies targeting calcium-dependent pathways for the treatment of acute and chronic conditions. Its lead candidate, CM4620, is designed to alleviate severe muscle cramps associated with sickle cell disease, highlighting the company’s commitment to addressing critical unmet medical needs. CalciMedica leverages a proprietary technology platform to create innovative calcium modulators and has a robust pipeline supported by an experienced management team and strategic partnerships aimed at accelerating clinical development. With a focus on transforming treatment landscapes, CalciMedica presents a distinctive investment opportunity in the biopharmaceutical sector.